Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China.
Department of Urology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen 529030, PR China.
Future Oncol. 2019 Jun;15(17):2009-2018. doi: 10.2217/fon-2018-0748. Epub 2019 Apr 1.
To study the expression of EIF5A2 in urinary tract urothelial carcinoma and its clinicopathological features and prognosis. EIF5A2 expression was detected via immunohistochemistry in 101 patients. Kaplan-Meier analysis showed that the EIF5A2 low expression group had significantly longer overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001) than the EIF5A2 high expression group. The high expression of EIF5A2 significantly predict poor OS and PFS in the subset patients (p < 0.05). EIF5A2 was an independent prognostic factor for OS and PFS (p = 0.003 and p = 0.001). The established nomogram model and its calibration curve predicted the probability of survival accurately. EIF5A2 is a potential molecular marker of poor prognosis in urinary tract urothelial carcinoma.
研究 EIF5A2 在尿路上皮癌中的表达及其临床病理特征和预后。通过免疫组织化学法检测 101 例患者的 EIF5A2 表达。Kaplan-Meier 分析表明，EIF5A2 低表达组的总生存（OS；p<0.001）和无进展生存（PFS；p<0.001）明显长于 EIF5A2 高表达组。EIF5A2 的高表达在亚组患者中显著预测 OS 和 PFS 不良（p<0.05）。EIF5A2 是 OS 和 PFS 的独立预后因素（p=0.003 和 p=0.001）。建立的列线图模型及其校准曲线准确预测了生存概率。EIF5A2 是尿路上皮癌不良预后的潜在分子标志物。
